Más-o-menos: A simple sign averaging method for discrimination in genomic data analysis

Bioinformatics

Volumn 30, Issue 21, 2014, Pages 3062-3069

  Zhao, Sihai Dave ^a   Parmigiani, Giovanni ^b,c   Huttenhower, Curtis ^b   Waldron, Levi ^d  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d CITY UNIVERSITY OF NEW YORK   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALGORITHM; BLADDER TUMOR; BREAST TUMOR; FEMALE; GENE EXPRESSION PROFILING; GENETICS; GENOMICS; HUMAN; OVARY TUMOR; PROCEDURES; SURVIVAL;

ALGORITHMS; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; GENOMICS; HUMANS; OVARIAN NEOPLASMS; SURVIVAL ANALYSIS; URINARY BLADDER NEOPLASMS;

EID: 84911394810     PISSN: 13674803     EISSN: 14602059     Source Type: Journal    
DOI: 10.1093/bioinformatics/btu488     Document Type: Article

References (65)

1. Als, A.B. et al. (2007) Emmprin and survivin predict response and survival following cisplatin-containing chemotherapy in patients with advanced bladder cancer. Clin. Cancer Res., 13, 4407-4414.
2. Bamber, D. (1975) The area above the ordinal dominance graph and the area below the receiver operating characteristic graph. J. Math. Psychol., 12, 387-415.
3. Bell, D. et al. (2011) Integrated genomic analyses of ovarian carcinoma. Nature, 474, 609-615.
4. Bentink, S. et al. (2012) Angiogenic mRNA and microRNA gene expression signature predicts a novel subtype of serous ovarian cancer. PloS One, 7, e30269.
5. Bernau, C. et al. (2012) survHD: Synthesis of Microarray-based Survival Analysis. R package version 0.5.0. https://bitbucket.org/lwaldron/survhd.
6. Bernau, C. et al. (2014) Cross-study validation for assessment of prediction models and algorithms. Bioinformatics, 30, i105-i112.
7. Blaveri, E. et al. (2005) Bladder cancer outcome and subtype classification by gene expression. Clin. Cancer Res., 11, 4044-4055.
8. Bonome, T. et al. (2008) A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer. Cancer Res., 68, 5478-5486.
9. Buhlmann, P, and Van De Geer, S. (2011) Statistics for High-dimensional Data: Methods, Theory and Applications. Springer, Heidelberg.
10. Colman, H. et al. (2010) A multigene predictor of outcome in glioblastoma. Neuro-oncology, 12, 49-57.
11. Crijns, A. et al. (2009) Survival-related profile, pathways, and transcription factors in ovarian cancer. PLoS Med., 6, e1000024.
12. Dave, S.S. et al. (2004) Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N. Engl. J. Med., 351, 2159-2169.
13. Davis-Stober, C. et al. (2010) A constrained linear estimator for multiple regression. Psychometrika, 75, 521-541.
14. Denkert, C. et al. (2009) A prognostic gene expression index in ovarian cancervalidation across different independent data sets. J. Pathol., 218, 273-280.
15. Desmedt, C. et al. (2007) Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the transbig multicenter independent validation series. Clin. Cancer Res., 13, 3207-3214.
16. Donoho, D. and Jin, J. (2008) Higher criticism thresholding: Optimal feature selection when useful features are rare and weak. Proc. Nat Acad. Sci. USA, 105, 14790-14795.
17. Dressman, H. et al. (2007) An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. J. Clin. Oncol., 25, 517-525.
18. Emura, T. et al. (2012) Survival prediction based on compound covariate under cox proportional hazard models. PLoS One, 7, e47627.
19. Eng, K.H. et al. (2013) Pathway index models for construction of patient-specific risk profiles. Stat. Med., 32, 1524-1535.
20. Ferriss, J.S. et al. (2012)Multi-gene expression predictors of single drug responses to adjuvant chemotherapy in ovarian carcinoma: predicting platinum resistance. PloS One, 7, e30550.
21. Foekens, J.A. et al. (2006) Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer. J. Clin. Oncol., 24, 1665-1671.
22. Friedman, J.H. (1997) On bias, variance, 0/1loss, and the curse-of-dimensionality. Data Min. Knowl. Discov., 1, 55-77.
23. Friedman, J.H. et al. (2010) Regularization paths for generalized linear models via coordinate descent. J. Stat. Softw., 33, 1-22.
24. Ganzfried, B.F. et al. (2013) curatedOvarianData: clinically annotated data for the ovarian cancer transcriptome. Database, 2013, bat013.
25. Haibe-Kains, B. et al. (2012) A three-gene model to robustly identify breast cancer molecular subtypes. J. Nat Cancer Inst., 104, 311-325.
26. Hallett, R.M. et al. (2010) An algorithm to discover gene signatures with predictive potential. J. Exp. Clin. Cancer Res., 29, 120.
27. Hand, D.J. (2006) Classifier technology and the illusion of progress. Stat. Sci., 21, 1-14.
28. Hastie, T. et al. (2005) The elements of statistical learning: data mining, inference and prediction. Math. Intell., 27, 83-85.
29. Hoerl, A. and Kennard, R. (1970) Ridge regression: biased estimation for nonorthogonal problems. Technometrics, 12, 55-67.
30. Kang, J. et al. (2012) A dna repair pathway-focused score for prediction of outcomes in ovarian cancer treated with platinum-based chemotherapy. J. Nat Cancer Inst., 104, 670-681.
31. Kim, W.J. et al. (2010) Predictive value of progression-related gene classifier in primary non-muscle invasive bladder cancer. Mol. Cancer, 9, 3.
32. Konstantinopoulos, P. et al. (2010) Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. J. Clin. Oncol., 28, 3555-3561.
33. Laughlin, J.E. (1978) Comment on Estimating coefficients in linear models: it dont make no nevermind. Psychol. Bull., 85, 247-253.
34. Leek, J.T. and Storey, J.D. (2007) Capturing heterogeneity in gene expression studies by surrogate variable analysis. PLoS Genet., 3, e161-e161.
35. Leek, J.T. et al. (2010) Tackling the widespread and critical impact of batch effects in high-throughput data. Nat. Rev. Genet., 11, 733-739.
36. Li, C. and Rabinovic, A. (2007) Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics, 8, 118-127.
37. Lin, D. and Wei, L. (1989) The robust inference for the Cox proportional hazards model. J. Am. Stat. Assoc., 84, 1074-1078.
38. Lindgren, D. et al. (2010) Combined gene expression and genomic profiling define two intrinsic molecular subtypes of urothelial carcinoma and gene signatures for molecular grading and outcome. Cancer Res., 70, 3463-3472.
39. Lovie, A. and Lovie, P. (1986) The flat maximum effect and linear scoring models for prediction. J. Forecast., 5, 159-168.
40. MAQC Consortium (2010) The microarray quality control (maqc)-ii study of common practices for the development and validation of microarray-based predictive models. Nat. Biotechnol., 28, 827-865.
41. Minn, A.J. et al. (2005) Genes that mediate breast cancer metastasis to lung. Nature, 436, 518-524.
42. Minn, A.J. et al. (2007) Lung metastasis genes couple breast tumor size and metastatic spread. Proc. Nat Acad. Sci. USA, 104, 6740-6745.
43. Mok, S. et al. (2009) A gene signature predictive for outcome in advanced ovarian cancer identifies a survival factor: microfibril-associated glycoprotein 2. Cancer Cell, 16, 521-532.
44. Reme, T. et al. (2013) Modeling risk stratification in human cancer. Bioinformatics, 29, 1149-1157.
45. Riester, M. et al. (2012) Combination of a novel gene expression signature with a clinical nomogram improves the prediction of survival in high-risk bladder cancer. Clin. Cancer Res., 18, 1323-1333.
46. Schmidt, M. et al. (2008) The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res., 68, 5405-5413.
47. Scholkopf, B, and Smola, A.J. (2002) Learning with Kernels: Support Vector Machines, Regularization, Optimization, and Beyond. MIT press.
48. Shaughnessy, J. et al. (2007) A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood, 109, 2276-2284.
49. Sjodahl, G. et al. (2012) A molecular taxonomy for urothelial carcinoma. Clin. Cancer Res., 18, 3377-3386.
50. Sotiriou, C. et al. (2006) Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J. Nat Cancer Inst., 98, 262-272.
51. Struthers, C. and Kalbfleisch, J. (1986) Misspecified proportional hazard models. Biometrika, 73, 363-369.
52. Symmans, W.F. et al. (2010) Genomic index of sensitivity to endocrine therapy for breast cancer. J. Clin. Oncol., 28, 4111-4119.
53. Tibshirani, R.J. (1996) Regression shrinkage and selection via the lasso. J. R. Stat. Soc. Ser. B, 58, 267-288.
54. Tibshirani, R.J. (1997) The lasso method for variable selection in the Cox model. Stat. Med., 16, 385-395.
55. Tothill, R. et al. (2008) Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin. Cancer Res., 14, 5198-5208.
56. Uno, H. et al. (2011) On the c-statistics for evaluating overall adequacy of risk prediction procedures with censored survival data. Stat. Med., 30, 1105-1117.
57. van Noort, V. et al. (2003) Predicting gene function by conserved co-expression. Trends Genet., 19, 238-242.
58. Verhaak, R.G. et al. (2013) Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J. Clin. Invest., 123, 517.
59. Verweij, P. and Van Houwelingen, H. (1994) Penalized likelihood in cox regression. Stat. Med., 13, 2427-2436.
60. Viechtbauer, W. (2010) Conducting meta-analyses in R with the metafor package. J. Stat. Softw., 36, 1-48.
61. Wainer, H. (1976) Estimating coefficients in linear models: it dont make no nevermind. Psychol. Bull., 83, 213-217.
62. Waldron, L. et al. (2014) Comparative meta-analysis of prognostic gene signatures for Late-Stage ovarian cancer. J. Nat Cancer Inst., 106, pii: dju049.
63. Wang, Y. et al. (2005) Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet, 365, 671-679.
64. Yoshihara, K. et al. (2010) Gene expression profile for predicting survival in advancedstage serous ovarian cancer across two independent datasets. PloS One, 5, e9615.
65. Yoshihara, K. et al. (2012) High-risk ovarian cancer based on 126-gene expression signature Is uniquely characterized by downregulation of antigen presentation pathway. Clin. Cancer Res., 18, 1374-1385.